Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients
France133 participantsStarted 2020-04-01
Plain-language summary
Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection
* Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia
* Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC)
Exclusion Criteria:
* No microbiological confirmation by respiratory specimen analyses
* Proved HIV infection
* Patient denied to particpate
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial has already been completed and was observational in nature, would you be able to help me find or access the results, and what do they tell us about how common Pneumocystis jirovecii pneumonia actually is in people with conditions like mine?
2Given that this study focused specifically on non-HIV immunocompromised patients, does my particular immune condition or the medications I'm on put me at a similar level of risk to the patients who were studied?
3Based on what this trial and other research show about PJP risk in people like me, should I be on preventive treatment such as prophylactic antibiotics, and what are the benefits and risks of that approach?
4Are there any ongoing or upcoming trials on PJP prevention or treatment that might be relevant for me, now that this observational study is complete?
5What warning signs of Pneumocystis jirovecii pneumonia should I watch for, and how quickly should I seek care if I notice them given my level of immune suppression?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients
Timeframe: Between the first january 2004 and the 31th december 2021